Prodrug–carboxypeptidase G2 therapy: certain concerns on carboxypeptidase G2

Tinghe Yu; Tianran Yu; Xinya Li

PMC · DOI:10.3389/fphar.2025.1560834·June 12, 2025

Prodrug–carboxypeptidase G2 therapy: certain concerns on carboxypeptidase G2

Tinghe Yu, Tianran Yu, Xinya Li

PDF

Open Access

Abstract

Linked entities

Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.

Genes1

ADA

Proteins1

Species2

Pseudomonas sp.(species)Homo sapiens(human · species)

Chemicals6

ZD2767P (His)4-[(2-chloroethyl) (2-mesyloxylethyl)amino]benzoyl-L-glutamic acid CMDA Met MTX

Diseases7

lymphoma cancer incoordination ovarian and lung cancers leukemia PK osteosarcoma

Mutations3

G122SI99TT328A

Figures1

Click any figure to enlarge with its caption.

Peer Reviews

No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.

Videos

No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.

Taxonomy

TopicsPeptidase Inhibition and Analysis · Adenosine and Purinergic Signaling · Diabetes Treatment and Management